| Literature DB >> 31749827 |
Aftab Alam1, Nikhat Imam1,2, Mohd Murshad Ahmed1, Safia Tazyeen1, Naaila Tamkeen3, Anam Farooqui1, Md Zubbair Malik4, Romana Ishrat1.
Abstract
Tuberculosis (TB) is one of deadly transmissible disease that causes death worldwide; however, only 10% of people infected with Mycobacterium tuberculosis develop disease, indicating that host genetic factors may play key role in determining susceptibility to TB disease. In this way, the analysis of gene expression profiling of TB infected individuals can give us a snapshot of actively expressed genes and transcripts under various conditions. In the present study, we have analyzed microarray data set and compared the gene expression profiles of patients with different datasets of healthy control, latent infection, and active TB. We observed the transition of genes from normal condition to different stages of the TB and identified and annotated those genes/pathways/processes that have important roles in TB disease during its cyclic interventions in the human body. We identified 488 genes that were differentially expressed at various stages of TB and allocated to pathways and gene set enrichment analysis. These pathways as well as GSEA's importance were evaluated according to the number of DEGs presents in both. In addition, we studied the gene regulatory networks that may help to further understand the molecular mechanism of immune response against the TB infection and provide us a new angle for future biomarker and therapeutic targets. In this study, we identified 26 leading hubs which are deeply rooted from top to bottom in the gene regulatory network and work as the backbone of the network. These leading hubs contains 31 key regulator genes, of which 14 genes were up-regulated and 17 genes were down-regulated. The proposed approach is based on gene-expression profiling, and network analysis approaches predict some unknown TB-associated genes, which can be considered (or can be tested) as reliable candidates for further (in vivo/in vitro) studies.Entities:
Keywords: DEGs; KEGG; LCP; gene knock-out; gene ontology; meta-analysis; network analysis
Year: 2019 PMID: 31749827 PMCID: PMC6844239 DOI: 10.3389/fgene.2019.00932
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Figure 1Functional Classification of Differentially expressed genes from various GSE series associated with TB disease according to (A) Molecular functions (Transporter activity [(U188,D286), Translation regulator activity(U03,D09), Catalytic activity(U978,D807), Channel regulator activity(U03,D13) Receptor activity(U219,D295), Signal transducer activity(U127,D144), Antioxidant activity(U08,D12), Structural molecule activity(U96,D101), Binding(U957,D1150) and unclassified(U53,D25)], (B) Biological processes [(cellular component organization or biogenesis(U108,D134), cellular process(U709,D790), localization(U198,D207), reproduction(U19,D23), biological regulation(U310,D383), response to stimulus(U267,D299), developmental process(U172,D213), rhythmic process(U01,D00), multicellular organismal process (U124,D129), locomotion(U48,D57), biological adhesion(U44,D34), metabolic process(U456,D471), growth(U10,D04), immune system process(U47,D48), cell killing (U00,D07) and unclassified(U119,D43)] and (C) Protein classes [(extracellular matrix protein(U52,D34), cytoskeletal protein(U101,D139), transporter(U126,D142), transmembrane receptor regulatory/adaptor protein(U11,D09), transferase(U226,D227), oxidoreductase(U132,D77), lyase(U21,D28), cell adhesion molecule(U76,D74), ligase(U63,D48), nucleic acid binding(U250,D318), signaling molecule(U205,D352), enzyme modulator(U267,D304),calcium-binding protein(U69,D63), defense/immunity protein(U58,D74), hydrolase(U363,D304), transfer/carrier protein(U50,D31), membrane traffic protein(U52,D60), transcription factor(U200,D222), chaperone(U19,D23), cell junction protein(U24,D28), surfactant(U03,D00), structural protein(U27,D20), storage protein(U03,D03), isomerase(U18,D11), receptor(U216,D241)]. (U, Up-regulated; D, Down-regulated).
Overrepresented PANTHER protein class and GO ontology categories of all differentially expressed genes.
| PANTHER Protein Classes | P-value | FDR |
|---|---|---|
| Chemokine | 2.14E−08 | 2.29E−06 |
| Cytokine | 6.71E−08 | 4.79E−06 |
| Hydrolase | 5.82E−06 | 3.11E−04 |
| Ribosomal protein | 1.44E−05 | 6.15E−04 |
| RNA-binding protein | 2.36E−05 | 8.42E−04 |
| Signaling molecule | 1.46E−04 | 4.45E−03 |
| Cell adhesion molecule | 2.97E−04 | 7.95E−03 |
| Protease | 4.81E−04 | 1.14E−02 |
| Receptor | 1.52E−03 | 3.25E−02 |
|
| ||
| Chemokine activity | 1.19E−06 | 7.52E−05 |
| Cytokine activity | 1.18E−06 | 1.12E−04 |
| Cytokine receptor binding | 5.29E−05 | 1.67E−03 |
| Oxidoreductase activity | 4.85E−04 | 1.02E−02 |
| Receptor binding | 5.61E−04 | 1.07E−02 |
| Hydrolase activity | 3.87E−06 | 1.84E−04 |
| Catalytic activity | 9.50E−08 | 1.81E−05 |
| Protein binding | 1.20E−04 | 3.25E−03 |
| Structural constituent of ribosome | 1.66E−04 | 3.95E−03 |
|
| ||
| Cytokine-mediated signaling pathway | 3.45E−08 | 4.21E−06 |
| Response to external stimulus | 3.75E−08 | 3.05E−06 |
| Response to interferon gamma | 1.65E−07 | 1.01E−05 |
| Immune response | 2.10E−07 | 1.02E−05 |
| Sensory perception of chemical stimulus | 2.15E−07 | 8.72E−06 |
| Locomotion | 3.38E−07 | 1.03E−05 |
| Signal transduction | 5.32E−07 | 1.44E−05 |
| Immune system process | 3.39E−06 | 8.27E−05 |
| Cell communication | 5.35E−06 | 1.19E−04 |
| Cell proliferation | 1.09E−05 | 2.23E−04 |
| Response to biotic stimulus | 1.59E−05 | 2.99E−04 |
| Intracellular signal transduction | 1.74E−05 | 3.03E−04 |
| Death | 4.17E−05 | 6.79E−04 |
| Cell death | 4.17E−05 | 6.36E−04 |
| Cellular component movement | 4.60E−05 | 6.61E−04 |
| Developmental process | 5.75E−05 | 7.80E−04 |
| Apoptotic process | 6.05E−05 | 7.77E−04 |
| Cellular process | 9.43E−05 | 1.15E−03 |
| Sensory perception | 9.74E−05 | 1.13E−03 |
| Response to stress | 1.04E−04 | 1.15E−03 |
| RNA metabolic process | 1.93E−04 | 2.04E−03 |
| MAPK cascade | 2.01E−04 | 2.05E−03 |
| Response to stimulus | 2.05E−04 | 2.00E−03 |
| Cellular defense response | 2.12E−04 | 1.99E−03 |
| Endocytosis | 3.17E−04 | 2.86E−03 |
| Receptor-mediated endocytosis | 7.23E−04 | 6.30E−03 |
| Lipid metabolic process | 9.30E−04 | 7.82E−03 |
| Negative regulation of apoptotic process | 1.01E−03 | 8.21E−03 |
| Behavior | 1.04E−03 | 8.15E−03 |
| Localization | 1.17E−03 | 8.90E−03 |
| Regulation of catalytic activity | 2.04E−03 | 1.51E−02 |
| Sulfur compound metabolic process | 2.06E−03 | 1.48E−02 |
| Cell adhesion | 2.78E−03 | 1.94E−02 |
| Biological adhesion | 2.78E−03 | 1.89E−02 |
| Cell surface receptor signaling pathway | 3.44E−03 | 2.27E−02 |
| Cellular component biogenesis | 3.88E−03 | 2.49E−02 |
| Cell–cell adhesion | 5.00E−03 | 3.13E−02 |
| Cellular amino acid catabolic process | 6.59E−03 | 4.02E−02 |
| Regulation of molecular function | 6.62E−03 | 3.94E−02 |
|
| ||
| Extracellular region | 6.21E−05 | 1.96E−03 |
| Extracellular space | 5.48E−04 | 1.15E−02 |
| Nucleus | 2.01E−03 | 3.17E−02 |
| Ribonucleoprotein complex | 8.32E−06 | 5.24E−04 |
| Nucleolus | 3.28E−03 | 4.13E−02 |
Overrepresentation was determined by calculating the probability that the number of differentially expressed genes belonging to a category is larger or smaller than what would be expected based on a reference human genome. P-values are adjusted using a Bonferroni correction.
The total number of DEGs from various GSE series associated with TB disease.
| Normal to Latent Infection | |
|---|---|
| Up-regulated | Down-regulated |
| IER5L, MS4A6A, DOK2, FZD2, NCKI-ASI, SNHG12, NLRC4, XPO7, SMA4, CD36, AFFI, NDUFS8 | IL1A, IL6, ACOD1, IL1B, ELOVL7, PTGS2, EREG, F3, IFIT1, TNF, KANK1, CCL4, CXCL11, PTX3, IRAK2, AREG |
| Normal to Active TB | |
| Up-regulated | Down-regulated |
| GBP5, ISG15, SAMD9L, SERPING1, ANKRD22, ETV7, EPSTI1, GBP4, RSAD2, AIM2, IFI44, IFIT3, FGL2, FYB, MNDA, PAX5, OAS3, OAS1, IFI6, TNFSF10, UBE2L6, XAF1, STAT1, BST2, IFI35, STAT2, IFI44L, TRIM22, IFIH1, IFITM1, ATF3, BATF2, IFITM3, GBP1P1, RTP4, FCGR1B, C1QB, CEACAM1, FBXO6, SAMD4A, FRMD3, CMPK2, SELL, CFH, TLR8, LGALS3BP, SRGAP2, SECTM1, NCF1, SIGLEC1, APOL1, TRIM14, MB21D1, CARD16, FGD2, RNF213, CD163, PML, OAS2, OR52K3P, LY6E, RABGAP1L, P2RX7, NRG1, FBXO32, TYMP, PSMB9, NCF1C, PNPT1, CXCL13, GMPR, LAMP3, HESX1, C3AR1, STAT4, CXCL11, IFIT2, STAP1, ZC3H12A, RCAN1, HERC6, CCL20, CD83, CRIM1, GCH1, OASL, DLL4, MX2, EIF2AK2, EBI3, AXL, MGLL, CD80, IFIT5, IFIT1, CCL8, NFE2L3, PLSCR1, ICAM1, CXCL9, SLAMF7, CXCL10, HERC5, VCAM1, DDX58, NFKB1, SAMD9, IGFBP3, CCL3, CD274, BIRC3, IRF1, TAP1, PARP14, TMEM140, WARS, CASP1, GBP2, PSTPIP2, PARP9, RNASE6, FAM129C, FZD2, CD36, LRRK2, MS4A6A, CCR2, NAIP, FCRL2, P2RY13, CLEC7A, PCDH9, CD300LF, CLEC4A, C10orf54, BAIAP2-AS1, C1orf162, SORT1, JAK2, VAMP5, SCO2, ODF3B, PSME2, LOC101930164, P2RY14, GBP1, GBP6, CARD17, FCGR1A | RNF141, SLC25A37, ID3, EMP2, SKP2, SLC2A3, SUN1, KIT, OLR1, FLNB, CCDC14, GAPT, DHRS9, IQGAP3, SESN3, GINS4, HIST1H4C, CD44, KANK1, KCNJ2, TNIP3, MIR146A, CXCL3, LOC644090, MSC, SOD2, NLRP3, SERPINB9, TNFRSF9, ARL5B, IL24, ADORA2A, PHLDA1, MYO10, CXCL8, DNAAF1, MIR3945HG, NR3C1, TNFAIP6, SERPINB2, TNF, MAP3K8, IL1A, AGO2, CSF3, SPAG9, KYNU, LOC440934, WNT5A, DENND4A, ACOD1, PTGS2, OSM, CCL4, PFKFB3, EREG, ITGB8, PTX3, IL36G, G0S2, SLC7A11, ZC3H12C, TNFAIP3, IL6, CCRL2, FERMT2, SLCO4A1, SGPP2, FOSL2, CCL23, FLT1, SERPINB8, NUP98, SLC35F5, MN1, DDIT4, NAMPT, IRAK2, IL10, SLC7A5, AK4, CXCL2, UPB1, CEMIP, ADGRG2, FEZ1, THBS1, LACC1, CXCL1, TRAF1, PHLDA2, HEY1, LRP12, UBTD2, SLC39A8, PLPP3, SLC7A1, ATXN1, KMO, FNDC3B, IL1B, C11orf96, F3, PSEN1, BCAT1, GEM, TFPI2, PLAUR, MAFF, TRIM36, ZNF697, INSIG1, DPYSL3, ATP2B1, NCR3LG1, MAMLD1, ZNF540 |
| Latent infection to Infection to Active TB | |
| Up-regulated | Down-regulated |
| CLEC12B, CD36, CORO1B, SIGLEC16, LINC00484, AK5, MS4A6A, GPBAR1, RTN1, CREB5, DPYD, LDB2, FCN1, LRRK2, RASSF4, ANXA4, LPCAT2, SKAP2, CPPED1, RNASE2, PLSCR3, CLEC12A, BST1, FGD2, RAB3D, FGL2, PYCARD, CEBPA, MNDA, CD33, PRAM1, LILRA1, SLC39A11, TNFSF13, SAMHD1, DIAPH2, FAR2, MSRB1, TBCK, FARS2, C14orf159, MSRB2, ATG16L2, DPYSL2, AIF1, HK3, SIGLEC7, FYB, RPS6KA4, TBC1D5, C10orf11, AGTRAP, PYGL, CARD9, NAGA, SLC9A9, C1RL, STX8, MTHFD1, KCTD12, CBR1, ASCL2, CPNE8, MBNL3, ANXA6, CALML4, HSDL2, SLC22A18, KDM1B, IDH1, DNAJC10, TBXAS1, SCLT1, HSD17B4, MGST2, NAIP, JAML, ENTPD1, ASGR1, BLVRB, AOAH, NIPAL2, NAAA, RAB24, TST, COMT, COMMD10, CYFIP1, TALDO1, ULK2, HDAC9, RBCK1, CEACAM4, OBFC1, FUCA2, NREP, STX10, AKR7A2, PLOD1, TRIOBP, QDPR, FAM172A, CDK19, DPAGT1, PARVG, CLEC4A, SSBP4, PNKP, FBXL5, ASRGL1, CARS2, ATP11A, PLXNC1, TSPO, ARHGEF6, AGPAT3, HEXDC, PDSS2, PGM2, PRKCB, H2AFY, S100A9, SNX15, NINJ2, MAP4, PSTPIP1, GSTK1 | IL1A, ITGB8, TFPI2, COL1A1, MET, SERPINB2, GPRC5A, SLC7A11, CYP1A1, RAB7B, B3GALT2, DUSP4, CXCL1, MMP19, THBS1, HEY1, PPP1R10, ADAMDEC1, PDE4DIP, CCRL2, LMNA, ZC3H12C, RGS13, CXCL5, PMEPA1, SKIL, LACC1, DPYSL4, ABCG1, AHRR, MIR155, EPHA4, CD109, MIR3945HG, NCR3LG1, WHRN, FAM177A1, SLC39A8, HEY2, C11orf96, KMO, CYP1B1, DUSP16, NFKB1, LZTS3, CXCR3, PLIN2, BIRC3, DOCK4, EPB41L3, MYO5C, ZHX2, CD58, P2RY10, CD82, MAPK8, PARD6G, NAB1, ABCB4, AMPD3, STK38L, SPECC1L, IL10RB-AS1, BANP, ETV6, PDCD4, MPZL3, CASC7, GGA2 |
These genes are classified into various categories of TB like normal to latent infections that contain 28 genes, normal to active TB diseases that contain 265 genes, and latent infection to active TB that contains 195 genes in this category.
Figure 2Venn diagram showing the number of common genes (in intersect region) which are differentially expressed among the normal vs. latent infection, normal vs. active TB, and latent infection vs. active TB.
Gene set enrichment analysis of differentially expressed genes (DEGs) among active TB, LTBI, and normal condition.
| Normal to Latent Infection | Normal to Active TB | Latent Infection to Active TB |
|---|---|---|
| Immune response | Inflammatory response | Response to stimulus |
| Inflammatory response | Immune response | Biological regulation |
| Transcription factor activity | Signal transduction | Localization |
| Transferase | Apoptotic process | Cell adhesion |
| Transporter | GTPase activity | Protein phosphorylation |
| MAPK cascade | Biological regulation | Immune response |
| Chemokine activity | Localization | Oxidoreductase activity |
| Cellular process | Angiogenesis | Hydrolase activity |
| Biological regulation | Cell adhesion | DNA-templated |
| Response to stimulus | Cellular process | Angiogenesis |
| Metabolic process | Response to stimulus | Binding |
| Protein binding | Metabolic process | Catalytic activity |
| Catalytic activity | Binding | Receptor activity |
| Bindings | Catalytic activity | Transporter activity |
| Signaling molecule | Receptor activity | Structural molecular activity |
| Signal transduction | ||
| Cellular process | ||
| Metabolic process |
Pathways enriched by differentially expressed genes (DEGs) among TB, LTBI, and healthy control (HC).
| Normal to Latent Infection | |||
|---|---|---|---|
| Up-regulated | Down-regulated | ||
| Transcriptional misregulation in cancer | AFF1 | Toll-like receptor | CCL4, CXCL11, IL1B, IRAK2, IL6, TNF |
| Phagosome, | CD36 | NF-Kappa B signaling pathway | CCL4, IL1B, PTGS2, TNF |
| Cytokin–cytokin receptor interaction | CCL4, IL1A, IL1B, IL6, PTGS2 | ||
| MAPK signaling pathway | IL1A, IL1B, TNF | ||
| Tuberculosis | IL1A, IL1B, IRAK2, IL6, TNF | ||
| Oxidative phosphorylation, non-alcoholic fatty liver disease (NAFLD, neurotrophin signaling pathway, Alzheimer’s disease | NDUFS8 | TNF signaling | IL1B, IL6, PTGS2, TNF |
| NOD-like receptor signaling pathway |
| ||
| Wnt signaling pathway | FZD2 | ||
|
| |||
|
|
| ||
| Cytokine–cytokine receptor interaction | CCL3, CCL8, CCR2, CXCL10, CXCL11, CXCL13, CXCL9, TNFSF10, TNF | Cell cycle | SKP2, IQGAP3, BCAT1, ID3, IL10, MAPK3K8, PHLDA1, PTGS2, THBS1, TRIM36 |
| Chemokine signaling pathway | CCL3, CCL8, CCR2, CXCL10, CXCL11, CXCL13, CXCL9, JAK2, NCF1, NFKB1, STAT1, TLR8, TNF | Chemokine signaling pathway | CCL20, CCL23, CCL4, CXCL1, CXCL2, CXCL3, CXCL8 |
| Toll-like receptor signaling pathway | CCL3, CXCL10, CXCL11, CXCL9, CD80, BIRC3, ITF1, IRAK2, NFKB1, STAT1, TLR8, TNF | NF-kappa B signaling pathway | CCL4, CXCL8, TNFAIP3, TRAF1, IL1B, PTGS2 |
| NF-kappa B signaling pathway | DDX58, BIRC3, ICAM1, NFKB1, TNF, VCAM1 | TNF signaling pathway | CCL20, CXCL1, CXCL2, CXCL3, TNFAIP3, IL1B, IL6, MAP3K8, PTGS2 |
| Transcriptional misregulation in cancer | ETV7, FCGR1A, IGFBP3, NFKB1, PAX5, PML | PI3K-Akt signaling pathway | DDIT4, KIT, CSF3, FLT1, ITGB8, IL6, OSM, THBS1 |
| Pathways in cancer | BIRC3, FZD2, NFKB1, PML, STAT1 | Metabolic pathways | AK4, UPB1, BCAT1, DHRS9, KYNU, KMO, NAMP, PLPP3, PTGS2 |
| MAPK signaling pathway | FLNB, IL1A, IL1B, MAP3K8 | ||
|
| |||
|
|
| ||
| Metabolic pathway | AGPAT3, AK5, BST1, CBR1, COMPT, DPYD, DPAGT1, HK3, HSD17B4, IDH1, LPCAT2, MTHFD1, PGM2, PYGL, QDPR, TST, TBXAS1, TALDO1 | Chemokine signaling pathway | CXCL1, CXCK5, CXCR3, NFKB1 |
| NOD-like receptor signaling pathway | NAIP, PYCARD, CARD9, PSTPIP1 | TNF signaling pathway | CXCL1, BIRC3, MAPK8, NFKB1 |
| Regulation of actin cytoskeleton | ARHGEF6, TRIOBP, CYFIP1, DIAPH2 | RAP1 signaling pathway | MET, DOCK4, PARD6G, THBS1 |
| Biosynthesis of antibiotics | AK5, HK3, IDH1, PGM2, TALDO1 | PI3K_AKT signaling | MET, COL1A1, ITGB8, NFKB1, THBS1 |
| Metabolism of xenobiotics by cytochrome p450 | AKR7A2, CBR1, GSTK1, MGST2 | Metabolic process | AMPD3, B3GALT2, CYP1A1, KMO |
| Thyroid hormone synthesis | ASGR1, CREB5, PRKCB | Apoptotic | CXCR3, ETV6, SKIL, BIRC3, CYP1B1, EPB41L3, HEY2, IL1A, LMNA, MAPK8, NFKB1, PDCD4, SERPINB2, THBS1 |
| Regulation of autophagy | PYCARD, TBC1D5, ATG16L2, LRRK2, ULK2 | Focal adhesion | MET, BIRCC3, COL1A1, ITGB8, MAPK8, THBS1 |
| Peroxisome | FAR2, GSTK1, HSD17B4, IDH1 | MAPK signaling pathway | DUSPI6, DUSP4, IL1A, MAPK8, NFKB1 |
| MicroRNAs in cancer | MET, CYP1B1, MIT155, NFKB1, PDCD4, THBS1 | ||
| Amoebiases | RAB7B, COL1A1, NFKB1, SERDINB2 | ||
Figure 3Topological properties of all the six networks. The behaviors of degree distributions (P[k]), clustering co-efficient (C[k]), neighborhood connectivity (CN[k]), betweenness (CB[k]), closeness (CC[k]), and eigenvector (CE[k]) measurements as a function of degree k. The lines are fitted lines with power laws in the data sets.
Figure 4Energy and modularity distribution in all networks quantified by Hamiltonian (HE) and modularity calculation as a function of network levels.
Figure 5This figure shown the fundamental key regulator from various stage of TB obtained from main networks to motif/hub level through various modules/sub-modules at various level of organization. The probability distribution of the 14 up-regulated key genes as a function of level of organization.
Figure 6This figure shown the fundamental key regulator from various stage of TB obtained from main networks to motif/hub level through various modules/sub-modules at various level of organization. The probability distribution of the 15 down-regulated key genes as a function of level of organization.
Figure 7This heatmap shows the 31 hub genes with their involvement in various biological processes.
Figure 8The molecular pathways associated with our key regulators were identified by KEGG pathway database. Out of the 31 key regulators, we did not find any pathways information of five genes namely: SAMD9L, IFI44L, IFI44, HERC5, and NF2L3.
Figure 9The changes in the exponents of the three important topological parameters (P[k]), C(k), and CN[k]) due to hub genes knock-out experiment from parent network.
Figure 10This figure shows the LCP-corr of all the modules/sub-modules of up-regulated genes at various levels. The compactness characterized by 2D plots between √(LCL) versus CA.
Figure 11This figure shows the LCP-corr of all the modules/sub-modules of down-regulated genes at various levels. The compactness characterized by 2D plots between √(LCL) versus CA.